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INTRODUCTION
Type 2 diabetes (T2DM) is a major health and eco-
nomic concern for the Western World. In the UK in 
2017, 26% of the population over 65 years are diag-
nosed, and 56% of these are men. The prevalence is 6 
times greater in men of South East Asian origin and 
3 times greater in men of Afro-Caribbean background 
[1]. In the USA, two-thirds of men over 65 years have 
T2DM [2]. 
Obesity is the most potent risk factor for T2DM. It 
accounts for 80% to 85% of the overall risk of develop-
ing T2DM and underlies the current global spread of 
the condition [1]. Other risk factors are lack of exer-
cise, family history, and gestational diabetes. In men, 
there is now strong evidence linking low testosterone 
to obesity, T2DM and components of the metabolic 
syndrome [1]. Several studies have shown high levels of 
hypogonadism (HG) in men with T2DM with around 
20% being overtly hypogonadal with total testosterone 
(TT) below 8 nmol/L and around 50% falling below the 
12 nmol/L level for mild HG [3]. In 2015, the American 
Association of Clinical Endocrinologists recommended 
that all men with T2DM should be screened for HG 
along with all men with body mass index (BMI) >30 
kg/m2 or waist circumference over 104 cm [4]. The 2018 
Endocrine Society guidelines, in contrast, continues to 
advise against any form of testosterone screening. Re-
cent re-classification of HG by the Endocrine Society 
refers to T2DM related HG as ‘functional’ and some 
endocrine guidelines [5] suggest that only ‘classical’ HG 
be treated, despite no published studies demonstrating 
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that this group responds better. On the contrary, evi-
dence suggests that men classified as ‘functional HG’ 
form the majority of patients showing benefit from 
clinical trials [6].
LOW TESTOSTERONE AND INCIDENT 
TYPE 2 DIABETES
The link between T2DM and HG is considered bi-
directional and conventional management has recov-
ered around lifestyle strategies of weight and exercise 
which are clearly failing as the prevalence continues to 
increase [7]. The evidence suggests that low testoster-
one leads to new onset T2DM and contributes to wors-
ening comorbidities [8-10].
In a study of 1,413 men, those in the first (lowest) 
tertile of low free testosterone (FT) and TT were four 
times more likely to have diabetes than those in the 
third tertile of low TT and FT [8]. Furthermore, low 
FT and sex hormone binding globulin (SHBG) have 
been shown to predict the onset of diabetes in men in 
up to 10 years of follow-up (odds ratio [OR], 1.58 for a 
decrease of 4 ng/dL FT and OR, 1.89 for a decrease of 
16 nmol/L SHBG) [9]. A meta-analysis of prospective 
studies, showed men with TT levels above 15.5 nmol/L 
had a 42% lower risk of incident diabetes (relative risk, 
0.58; 95% confidence interval [CI], 0.39 to 0.87) compared 
with men with a TT of no greater than 15.5 nmol/L [11]. 
In a 2011 meta-analysis Corona et al’s study [11], found 
baseline TT was 2.08 nmol/L (95% CI, 3.57 to 0.59) lower 
in men who developed incident T2DM compared with 
those who did not. A major reason for this diminished 
relationship in some studies was adjustment for cen-
tral fat by waist circumference. In addition, individual 
studies lacked power because only of the low rates of 
incident diabetes. 
Several longitudinal studies have shown that low 
levels of TT and FT independently predict the later de-
velopment of T2DM or metabolic syndrome [12-18].
In the largest study to date, Holmboe et al [19] re-
ported on 5,250 men from the Danish population fol-
lowed-up for 29 years and showed that low TT and low 
SHBG were strongly associated with incident T2DM. 
There were 35/599 (lowest quartile of TT) vs. 13/599 
(highest quartile of TT) (p=0.13) in the non-smokers, 
corresponding values were 48/660 vs. 17/658 (p=0.034). 
As there was no effect of luteinizing hormone, the 
authors concluded that ‘primary hypogonadism’ was 
not a risk ‘factor’ for T2DM but that low TT should be 
considered a risk ‘marker’ for T2DM. As there were no 
data on testosterone therapy reported by Holmboe et al 
[19], a causal relationship could not be established.
LOW TESTOSTERONE AND 
INCREASED CARDIOVASCULAR AND 
ALL-CAUSE MORTALITY
Numerous long-term studies, and various reviews 
and meta-analyses, have provided evidence to support 
the association between testosterone deficiency (TD) 
and increased cardiovascular (CV) and all-cause mor-
tality [20-25], although evidence for a pathogenic link is 
lacking [26,27].
A systematic review and meta-analysis evaluating 
the association between endogenous testosterone and 
mortality concluded that low levels of  endogenous 
testosterone are associated with an increased risk of 
all-cause and CV death in community-based studies 
of men, with a reduction of 2.1 standard deviations in 
TT being associated with a 25% increase in mortality. 
However, most of the studies had issues with cohort 
selection and choice [20,21]. 
Two systematic reviews and meta-analyses evaluat-
ing the association between endogenous testosterone 
and all-cause mortality and cardiovascular disease 
(CVD) mortality [20] reported a protective effect of 
increased TT. Research examining the data from 1,954 
subjects, in terms of several statistical models, found 
that even after strict adjustment for comorbidities, 
there was a consistent link between testosterone level 
and mortality risk throughout, without proving causa-
tion [28]. 
In a prospective study involving 581 men with T2DM, 
patients were followed-up for a mean of 5.81 years. Low 
testosterone was defined as TT<10.4 nmol/L. Fifty-one 
men received testosterone therapy for at least 2 years. 
The mortality rates were 20% in the low testosterone 
group vs. 9.1% in the normal testosterone group, inde-
pendent of comorbidities and therapies, and 9.4% in 
those with TD in the treated group [23]. 
In a 10-year Australian study involving 3,690 older 
men, TT and FT levels in the normal range were as-
sociated with reduced all-cause and CV mortality. This 
was the first evidence to suggest that that both low 
and high levels are associated with all-cause mortality, 
and higher levels of dihydrotestosterone (DHT) reduce 
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CV risk [24].
A Swedish study involving 1,109 subjects aged 40 
years and over, with a mean follow-up of 14.1 years, 
suggested a strong association between low baseline 
testosterone and incident myocardial infarction (MI) 
[25].
Although these studies demonstrated a consistent as-
sociation between low testosterone and CVD incidence 
and mortality, this did not prove a pathogenic link. 
However, the conclusions from a review on testosterone 
and mortality were that low testosterone could be a 
‘marker’ of illness [27,28].
METABOLIC EFFECTS OF 
TESTOSTERONE THERAPY IN TYPE 2 
DIABETES
Low testosterone has been demonstrated to be closely 
linked with components of the metabolic syndrome in 
T2DM [11]. The mainstay of modern therapy for T2DM 
is directed to the reduction of CV risk. Smoking ces-
sation, reduction and exercise have been shown to im-
prove insulin sensitivity and should always be offered 
in conjunction with other therapies [29]. Aggressive 
management of dyslipidaemia and hypertension had 
led to National Institute for Health and Care Excel-
lence (NICE) guidance that all men with T2DM being 
offered metformin, statin, and angiotensin-converting 
enzyme inhibitor at initial diagnosis in all patients 
with T2DM unless contraindicated [29].
THE IMPORTANCE OF GLYCAEMIC 
CONTROL
The main target to improve outcome in T2DM has 
traditionally been improved glycaemic control as as-
sessed by HbA1c or more recently by International 
Federation of Clinical Chemistry and Laboratory Med-
icine [29]. Insulin resistance, as measured by the Ho-
meostatic Measurement of insulin resistance (HOMA-
IR) is known to be an independent risk factor for CV 
events [30] and the gold standard for assessment of 
change in insulin resistance. Bonora et al [30] reported 
that each unit change in HOMA-IR was associated 
with a 50% increase in CV events. In the UK Prospec-
tive Diabetes Study trial, each 1% increase in HbA1c 
was associated with a 21% increase in death, 14% in-
crease in MI and 43% increase in peripheral vascular 
disease [31]. Intensive management with metformin vs. 
conventions management was shown to reduce HbA1c 
from a mean of 7% at baseline to 6.2% at 12 months, 
but long-term follow-up over 10 years plus have shown 
that Hb1c levels rises with time and that weight loss 
is not maintained [32]. We therefore need alternative 
strategies as eventually many patients fail with a re-
gime dedicated to lifestyle change and hypoglycaemic 
drugs.
TESTOSTERONE THERAPY AND 
GLYCAEMIC AND METABOLIC 
CONTROL
Prospective, observational studies show that visceral 
adiposity, smoking and the metabolic syndrome predict 
the development of low testosterone levels [33,34]. Large 
prospective USA cohort studies [35] and in Germany 
[36] men showed that weight gain and development 
of diabetes or the metabolic syndrome accelerated the 
age-related decline in testosterone. In men with T2DM 
followed longitudinally, changes in testosterone levels 
over time correlated inversely with changes in insulin 
resistance, suggesting that improved lifestyle factors 
or altered pharmacological management that improved 
insulin sensitivity may also contribute to increased tes-
tosterone levels [37]. Observational studies found that 
both weight loss and exercise increase testosterone lev-
els [38]. Bariatric surgery improves glycaemic control 
and testosterone levels but there are clearly implica-
tions of cost and the selection of appropriate patients 
[38].
Early trials in obese men without T2DM yielded 
variable results. However, a 4.3-year follow-up from 
European Male Ageing Study [39] found that biochemi-
cal reversal of secondary HG was not associated with 
improvement in symptoms. And a placebo controlled 
randomized controlled trial (RCT) in obese hypogonad-
al men treated with severe weight reduction and either 
long acting testosterone undecanoate (TU) injections or 
placebo for 12 months, found that although weight and 
BMI loss was achieved in both groups, only the TU 
group preserved lean muscle and achieved symptom-
atic benefit [40,41]. This study provides strong evidence 
for the benefits of testosterone therapy for longer than 
6 months combined with life-style for men with HG 
and metabolic syndrome (Fig. 1).
A large-scale study in the Australia, the T4D study 
https://doi.org/10.5534/wjmh.180027
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is due to report on the possible reduction of incident 
diabetes by treating younger obese men with metabolic 
syndrome with TU [42].
In a small study of 24 patients, Kapoor et al [43] 
found that Testosterone Enanthate every 2 weeks for 
12 weeks lowered HOMA-IR by 1.7 units and HbA1c by 
0.37%, with slight reduction in total cholesterol. 
The Moscow study involved 184 obese men ran-
domised to long acting TU for 26 weeks found marked 
reductions in weight, BMI, waist circumference, and 
inflammatory markers but no reduction in fasting glu-
cose [44]. 
The TIMES2 study involved 220 men with either 
T2DM or metabolic syndrome treated for 26 weeks 
with 2% testosterone gel followed by an open label 
phase. There was a significant reduction in HOMA-IR 
at 12 months (p=0.006) but although the HbA1c fell by 
0.4% at 12 months, in men with T2DM, this just failed 
to reach significance. As the randomisation phase last-
ed only 6 months, there was possible selection bias for 
those men continuing to the open label phase and the 
drop-out rate was rather high at 29% [45].
The largest RCT conducted to date exclusively in 
men with T2DM is the BLAST study (an acronym of 
the towns and cities involved–Birmingham, Lichfield, 
Tamworth, Atherstone and Sutton Coldfield). This in-
volved 857 men screened from 7 UK general practice 
diabetes registers to provide 199 men detected with 
TT<12 nmol/L or FT<0.25 nmol/L (mild HG group) or 
TT<8nmol/L or FT<0.18 nmol/L (severe HG) group. 
Men were randomised to TU 1,000 mg or placebo injec-
tions, initially after 6 weeks and then 12 weeks for a 30 
weeks intervention period [38]. There was a significant 
treatment effect in HbA1c in the poorly controlled men 
(HbA1c≥7.5%) of 0.4% at 30 weeks and a significant ef-
fect in the well-controlled (<7.5%) at 18 weeks (p=0.002) 
but not at 30 weeks. A likely explanation for this was 
the impact of diet and lifestyle advice given at baseline 
for all patients and the likelihood that the additional 
impact was this was diminished by 30 weeks. There 
were significant reductions in weight, BMI, and waist 
circumference, plus marked improvement in sexual 
function and quality of life scores. These parameters 
continued to improve in the 12 months open label 
phase. HOMA-IR was unchanged during the 30-week 
RCT but fell by 1.5 units in the 12 months open label 
phase, along with marked falls in insulin levels in the 
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Fig. 1. Changes from baseline in body composition after 56 weeks 
treatment with intramuscular testosterone undecanoate (plus in-
tense exercise) or placebo (plus intensive exercise). Data from Ng 
Tang Fui et al (BMC Med 2016;14:153) [41].
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open label phase. Once again, interpreting data from 
the 106 patients in the open label phases must consider 
selection bias, as analysis showed that the decisions to 
proceed to the open label phase was driven by improve-
ments in sexual function (Fig. 2) [46].
Dhindsa et al [47] studied 94 men with T2DM, 50 
eugonadal and 44 with hypogonadotrophic hypogonad-
ism (HH), randomised to either testosterone cypionate 
250 mg every 2 weeks or placebo injection for 24 weeks. 
Men with HH had higher subcutaneous and visceral 
fat mass than eugonadal men. Insulin sensitivity mea-
sured by glucose infusion rate (GIR) was 36% lower in 
men with HH. GIR increased by 32% after 24 weeks of 
testosterone therapy but did not change after placebo 
(p=0.03 for comparison). HOMA-IR improved by 1.4% in 
the treatment (p=0.03) and was unchanged with place-
bo. There was a decrease in subcutaneous fat mass (23.3 
kg) and increase in lean mass (3.4 kg) after testoster-
one treatment (p<0.01) compared with placebo. Visceral 
and hepatic fat did not change. The expression of insu-
lin signalling genes (IR-b, IRS-1, AKT-2, and GLUT4) 
in adipose tissue was significantly lower in men with 
HH and was up-regulated after testosterone treatment. 
Testosterone treatment also caused a significant fall in 
circulating concentrations of free fatty acids, C-reactive 
protein, interleukin-1β, tumour necrosis factor-α, and 
leptin (p<0.05 for all).
A 5-year study of 40 obese hypogonadal men, 20 
treated with TU and 20 randomised to control, showed 
reductions in weigh (15%), waist circumference (10 cm), 
and HbA1c (1.5%), and 2.15-point reduction in HOMA-
IR [48].
Long term registry studies have shown reductions in 
weight, BMI, waist circumference, and HbA1c main-
tained for up to eight years [49,50].
Gianatti et al [51] conducted a 40-week study of TU 
vs. Placebo in 88 obese men with T2DM (mean age, 62 
years) and concluded that there was no significant im-
pact on HOMA-IR or HbA1c but there was a reduction 
in fat mass and increase in lean muscle mass. However, 
the treatment group were notably less obese (93 kg vs. 
101.5 kg) with baseline HOMA-IR of 2.1 falling to 1.75 
(p=0.08). Baseline HbA1c was 6.8%. This suggests that 
patients were well controlled with minimal insulin 
resistance suggesting that the study might have been 
under-powered for this cohort.
TESTOSTERONE AND SEXUAL 
FUNCTION IN TYPE 2 DIABETES
Men with T2DM have erectile dysfunction (ED) due 
to multiple comorbidities, most notably macro- and mi-
cro-vascular disease, autonomic and peripheral neurop-
athy, depression, and multiple medications in addition 
to HG [52]. Zitzmann et al [49,53] found that falling 
testosterone levels significantly impact on ED around 
8 nmol/L and Buvat et al [54] described a threshold of 
10.4 nmol/L where testosterone therapy might salvage 
men who fail with phosphodiesterase type 5 (PDE5) 
inhibitors. Men with T2DM also have significantly 
reduced responses to conventional ED therapy, due to 
multiple comorbidities [55]. Hackett et al [3,56] screened 
a UK population of men with T2DM and found that 
the impact of HG on ED was greatest in men with 
TT below 8 nmol/L, in agreement with the findings of 
Zitzmann et al [53]. These findings suggest that there 
are pitfalls in drawing conclusions from studies of tes-
tosterone therapy where men with T2DM form only a 
minor subgroup. Correcting the low testosterone levels 
will usually only address the ED burden due to HG but 
still leave the impact due to other comorbidities [56], 
which will need to be addressed by additional specific 
therapies [56]. Some trials only evaluated ED using in-
ternational index of erectile function-5 (IIEF-5), which 
only evaluates erections, whereas testosterone is in-
volved in desire, sexual frequency, orgasm, ejaculation, 
sensation, and sexual satisfaction [57].
The BLAST study [57], involving 199 men (mean age, 
61 years) with T2DM treated with TU, 1,000 mg for 30 
weeks with 12-month open label follow-up. Based on 
the finding from population screening and Zitzmann 
et al [53], this study evaluated men in the mild HG 
(8–12 nmol/L) and severe HG (below 8 nmol/L) and 
found that the improvement in the severe group at 
30 weeks was 3.9 points (5.8 points vs. placebo) (Fig. 
3), equated to the difference between the groups at 
baseline screening, suggesting that this was correcting 
the disease burden due to HG. Improvements reached 
highest significance at 6 months, suggesting that stud-
ies of less than 6 months were of insufficient duration. 
In the sub-group of men taking a PDE5 inhibitor, the 
improvement at the end of the open label phase was 
9.5 points in IIEF-EF, stressing the important of treat-
ing the multiple comorbidities. In the mild HG group, 
there was no improvement in IIEF-EF score, vs. pla-
https://doi.org/10.5534/wjmh.180027
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cebo. There were brisk improvements in sexual desire 
in both groups, most marked in the severe group and 
prompt improvement in desire predicted later improve-
ment in IIEF-EF. Men with depression, 23% of the 
group, showed little response by 30 weeks [50], which is 
in line with other studies looking at multiple parame-
ters in T2DM where therapeutic responses were strong 
influenced by depression [57]. Meta-analyses have 
shown depression to be strongly linked with sexual 
dysfunction in T2DM, yet the impact has been largely 
ignored [58].
The TIMES-2 study [45] involved 12 months RCT of 
2% testosterone gel in 220 men (mean age, 59 years) 
with either T2DM (62%) or metabolic syndrome with a 
4.87-point improvement in IIEF-EF score from a base-
line of 12 points. Unfortunately, the drop-out rate was 
29% which might reflect an issue related to gel, where-
as BLAST involved injections administered by the 
nurse involved in the patient’s normal diabetes care.
In the testosterone trials [59], involving older mean 
(mean age, 72 years) 37% of 780 recruited patients had 
T2DM. The IIEF-EF score increased by 2.64 points vs. 
placebo, but sexual activity increased to 4 times per 
week, along with significant increase in sexual desire. 
The authors described this improvement as ‘modest’. 
The disproportionate increase in desire and sexual ac-
tivity in proportion to EF scores is probably related to 
age associated comorbidities as shown by the high coro-
nary atheroma burden in the CV arm of the study. The 
authors concluded that PDE5 inhibitors might have 
produced a greater effect than testosterone therapy, 
quoting Spitzer et al [60]. They might, however have 
underestimated the benefits of increased sexual activ-
ity and desire in the context of the relationship of the 
couple. It is unlikely that PDE5 inhibitors alone would 
have been effective in this group, without the benefits 
in sexual desire associated with testosterone therapy 
in men with levels below 8 nmol/L [56]. Patients with 
HG were excluded from the regulatory trials of PDE5 
inhibitors such that it is inappropriate to extrapolate 
response rates from studies in the eugonadal popula-
tion [55]. The evidence suggests that older men with 
T2DM need a PDE5 inhibitor plus normalisation of 
testosterone levels [55,61]. The study by Spitzer et al [60] 
involved a population who had an excellent response to 
pre-treatment with sildenafil with an increase of over 
3 nmol/L from baseline, such that the mean TT at ran-
domisation to testosterone therapy was 12.63 nmol/L 
(up from 8.61 at baseline) meaning that 50% did not fit 
their criteria for HG and therefore would not expect to 
benefit from testosterone therapy. Despite these weak-
nesses, the effect of testosterone replacement therapy 
(TRT) was close to significance, even though the expo-
sure to testosterone was only 3 months. Paradoxically, 
despite recognising the effect of PDE5 inhibitors in 
the Spitzer study, only 1 of the long term longitudinal 
studies of testosterone included data on PDE5 inhibitor 
use, reporting a 12% use at baseline, increasing to 50% 
in 4 years of follow-up in the men taking testosterone 
[62].
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Fig. 3. Changes in international index of erectile function (IIEF) from baseline with 30 weeks double blind therapy with intramuscular testoster-
one undecanoate (TU) or placebo (P) in men with type 2 diabetes and mild hypogonadism (HG) (8–12 nmol/L) or severe HG (<8 nmol/L). Data 
from Hackett et al (Int J Clin Pract 2014;68:203-15) [46].
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META-ANALYSES
Several meta-analyses have considered the impact of 
testosterone therapy on metabolism but, far from clari-
fying the issue, in some cases they create confusion [63]. 
The highest level of evidence comes from RCTs, but 
many are of insufficient duration, often less than 26 
seeks and sometimes only 12 weeks (mean, 33.5 weeks) 
[64]. Many involve mixed populations such that it is 
doubtful that changes in insulin resistance or HbA1c 
can be achieved in men without significant insulin 
resistance [64,65]. These analyses are likely to be of in-
sufficient duration to answer questions as to CV safety 
of major adverse coronary events (MACE) [65]. Many 
studies on this subject exclude the first 6 months on 
the basis that events in this period are likely to be due 
to the untreated condition rather than the impact of 
therapy [23]. Different therapies are analysed together, 
often patches, oral medication, or implants that are 
largely obsolete or withdrawn [66]. Injections of differ-
ent esters are grouped together, and USA studies do 
not include long acting TU, a major therapy in Europe 
for over a decade [56,66]. The inclusion of longitudinal 
studies creates bias related to inaccurate initial diag-
nosis, lack of follow-up diagnosis and little evidence of 
therapy compliance [65]. Recent evidence suggests a po-
tential CV benefit from taking PDE5 inhibitors, often 
co-prescribe with testosterone therapy and this is also 
likely to be associated with men in stable long-term 
relationships associated with health and socio-economic 
benefits [67]. Many longitudinal studies have failed to 
address these issues [68,69]. The inclusion or exclusion 
of a small number of controversial studies can pro-
foundly alter the conclusions [68,70].
In contrast a comprehensive meta-analysis of 156 
RCTS by Huo et al [68] concluded that there the pre-
scription of testosterone supplementation for low-T for 
CV health, sexual function, physical function, mood, or 
cognitive function is without support from RCT. There 
was no analysis of data related to insulin resistance 
and no attempt to conduct a sub-analysis of men with 
cardiometabolic disease. PDE5 inhibitor use was not 
recorded.
A recent meta-analysis by Ponce et al [69] concluded 
that testosterone therapy improved sexual desire, ED, 
sexual satisfaction but increased erythrocytosis. A me-
ta-analysis by Corona et al [70] involving 59 RCTs in-
volving 3,029 treated and 2,049 controls concluded that 
there was clear evidence that TRT reduced fat mass 
and increased lean muscle mass (Fig. 4). They also con-
cluded that TRT improved insulin resistance and gly-
caemic control with results being more marked in me 
with metabolic disease [70]. There were non-significant 
effects on lipids or blood pressure. The same group also 
concluded that TRT improved sexual desire and erec-
tile function [65] and that there was no suggestion of 
Body composition
Weight (kg)
Waist circumference (cm)
BMI (kg/m )
Fat mass*
Lean mass*
Glyco-metabolic profile
Fasting glycemia (mM)
HOMA index
Total Cholesterol (mM)
Triglycerides (mM)
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Blood pressure
SBP (mmHg)
DBP (mmHg)
2
32
17
29
42
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23
16
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33
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17
16
0.43
0.66
0.25
0.32
0.51
0.34
0.80
0.12
0.08
0.03
0.94
0.95
0.54
2.66
0.09
0.44
0.37
0.51
1.16
0.25
0.18
0.08
1.08
0.66
1.39
1.35
0.58
0.19
0.66
0.17
0.45
0.01
0.01
0.01
2.96
2.54
0.39
0.52
0.15
0.00
0.00
0.00
0.00
0.08
0.09
0.18
0.36
0.25
Source #Trials
Mean diff
Diff in mean LL UL p-value
3 2 1 0 1 2 3
Testosterone . placebovs
Fig. 4. Meta-analysis of 59 randomized 
controlled trials of testosterone substitu-
tion in hypogonadism (3,029 treated vs. 
2,049 controls) (mean duration=32.5 
weeks). Highlight boxes indicate signifi-
cant changes. diff: difference, LL: lower 
limit, UL: pper limit, BMI: body mass 
index, HOMA: homeostatic model assess-
ment, HDL: high density lipoprotein, SBP: 
systolic blood pressure, DBP: diastolic 
blood pressure. Cited from Corona et al 
(Eur J Endocrinol 2016;174:R99-116) [70].
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increased CV risk and evidence of a reduction in all-
cause mortality in men with cardiometabolic disease, 
such as T2DM and metabolic syndrome [64]. These 
findings suggest that men with T2DM and metabolic 
syndrome are likely to see the greatest benefits from 
TRT and that these benefits might be underestimated 
when meta-analyses combine these men with younger 
cohorts.
TESTOSTERONE THERAPY, 
CARDIOVASCULAR AND ALL-CAUSE 
MORTALITY IN TYPE 2 DIABETES
Numerous long-term studies, and various reviews 
and meta-analyses, have provided evidence to support 
the association between HG and increased CV and all-
cause mortality. A systematic review and meta-anal-
ysis evaluating the association between endogenous 
testosterone and mortality concluded that low levels 
of endogenous testosterone are associated with an in-
creased risk of all-cause and CV death in community-
based studies of men, with a reduction of 2.1 standard 
deviations in TT being associated with a 25% increase 
in mortality. However, most of the studies had issues 
with cohort selection and choice [20,21]. These studies 
suggest that taking no action, or not measuring testos-
terone at all, is likely to have severe implications for 
men with T2DM and low testosterone [71].
MECHANISMS FOR POSSIBLE 
INCREASED CARDIOVASCULAR RISK
Adverse CVD events associated with testosterone 
therapy may stem from a 6% increased rate of polycy-
thaemia related to multiple mechanisms. The conver-
sion of testosterone to oestradiol stimulates erythropoi-
esis in the bone marrow. Testosterone also stimulates 
the synthesis of erythropoetin in the kidney, subse-
quently erythropoiesis, and the testosterone-induced 
increase of hepatic transcription factors, resulting in a 
reduction hepcidin from increased iron usage. Supra-
physiologic levels of testosterone observed with short-
acting injections may amplify this effect as may the 
conversion of testosterone gels to DHT, via the action 
of 5-α reductase in skin. Increased DHT levels may be 
associated with an increased risk of fluid retention and 
thrombosis, resulting in hypertension and heart failure 
[72]. No studies, however, have demonstrated increase 
risk of deep vein thrombosis [73]. Studies with high 
doses of testosterone have described reduced levels of 
high density lipoprotein cholesterol and adiponectin 
[72].
STUDIES SUGGESTING INCREASED 
CARDIOVASCULAR RISK
A retrospective USA study [74] involved 8,709 men 
with a baseline TT of ≤10.4 nmol/L who were undergo-
ing angiography. During a mean follow-up of 840 days, 
681 of the 7,486 patients not receiving testosterone 
therapy died, 420 suffered MIs and 486 experienced 
strokes. Of the 1,223 patients receiving testosterone 
therapy, 67 died, 23 suffered MIs and 33 experienced 
strokes. Complex statistical analysis, using more than 
50 covariates, concluded that there was a greater risk 
in the testosterone therapy group. However, there were 
concerns regarding the exclusion of 1,132 patients who 
experienced events because they were prescribed tes-
tosterone therapy after the event, when they should 
have been included in the untreated group, increasing 
the events by 70%. There was also no data confirming 
a correct diagnosis of TDS before testosterone therapy 
and none on compliance. Furthermore, some patients 
did not continue testosterone therapy, and mean TT 
levels were at the lower end of normal, suggesting 
many were undetected. When challenged, the authors 
revised the number to 132, but admitted that 104 wom-
en had been mistakenly included in the results.
A study analysing prescribing data in men treated 
with testosterone therapy [75], without records of blood 
results or symptoms, defined non-fatal coronary events 
as the major endpoint, assessed in the 12 months before 
and 3 months after therapy. However, the benefits of 
testosterone therapy take longer than this to appear 
and other studies have excluded the first 3 months 
treatment from analysis due to the likelihood of events 
relating to the pre-existing condition. Crucially, data on 
fatal CV events and all-cause mortality data was not 
collected, despite testosterone therapy in other studies 
having a major impact on mortality rather than event 
numbers. Twelve-month post-treatment data were col-
lected but not presented. Prior to treatment, the event 
rates within the groups were strangely identical. There 
was a small increase in non-fatal cardiac events in men 
taking testosterone therapy, which was more marked 
in those with increased risk. Overall, events were lower 
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than predicted from comparable research. The lack of 
mortality data demonstrates a failing to realise that a 
treatment that reduced mortality was likely to increase 
non-fatal events. In addition, the study design was not 
prospective, which casts doubts on the validity of ret-
rospective assessment for the 12-month pre-treatment 
period.
STUDIES SUGGESTING REDUCTION 
IN CARDIOVASCULAR EVENTS
The various metabolic benefits in terms of improved 
insulin resistance, reduced fat mass, increased lean 
muscle mass, and reduction in inflammatory markers 
might be expected to translate into a reduction in CV 
risk. Inadequate therapy might leave the patient at in-
creased risk of undertreated HG, such that trials need 
to be assessed in terms of adequate compliance and 
evidence of sustained treatment to therapeutic levels 
[47,76].
Two longitudinal studies have assessed long term 
mortality, exclusively in men with T2DM.
In a prospective study involving 587 men with T2DM 
[23], patients were followed-up for a mean of 5.81 years. 
Low testosterone was defined as TT<10.4 nmol/L. Fifty-
eight men received testosterone therapy for at least 2 
years. The mortality rates were 20% in the untreated 
group vs. 9.1% in the untreated group, independent of 
comorbidities and therapies, and 8.6% in the treated 
group.
Another prospective study followed-up 857 men with 
T2DM for 4 years after baseline testosterone measure-
ment [62]. Patients were randomised to either long act-
ing TU or placebo. Results showed that low baseline 
TT and FT were associated with increased all-cause 
mortality. Testosterone therapy and the use of PDE5 
inhibitors were independently associated with reduced 
all-cause mortality, with the greatest benefit from both 
treatments being seen in older men [62,67]. A major 
strength of this study was clear record of all testoster-
one doses administered and accurate recording of all 
medications, including PDE5 inhibitors (Fig. 5, 6).
These findings of reduced mortality in men taking 
PDE5 inhibitors is in close agreement with Anderson 
et al [77] who followed-up 5,956 men with T2DM over 6.9 
years. A 31% reduction in all-cause mortality and 26% 
reduction in MI were reported with a low rate of PDE5 
inhibitor prescribing at 22.8%. Earlier safety data from 
licensing studies showed similar trends but mortality 
reduction was not a primary outcome and studies were 
powered to show safety and not benefit. Postulated 
mechanisms are postulated as protection against endo-
thelial reperfusion injury, improved endothelial func-
tion and reduced systemic and pulmonary blood pres-
sure [78]. Unfortunately, testosterone levels were not 
recorded in this study. Andersson et al [79] followed-up 
43,415 men after first MI for 5 years and found signifi-
cant reduction in all-cause and CV mortality and 30% 
reduction in new diagnosis in heart failure and related 
admissions, in men prescribed PDE5 inhibitors. The 
benefits appeared dose related and were not seen with 
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other ED therapies.
In a retrospective study involving 1,031 hypogonadal 
men, 372 of whom took T therapy, the cumulative 
mortality was 21 %in the untreated group vs. 10 % in 
the treated group. The greatest effect was observed in 
younger men and those with T2DM [80].
In a virtual controlled study, researchers examined 
electronic medical records between 1996 and 2011 to 
identify 5,695 men with a low initial TT level, a subse-
quent testosterone level, and up to 3 years of follow-up 
[81]. Testosterone levels were correlated with the use of 
testosterone supplementation. The primary outcomes 
were a composite of death, nonfatal MI, and stroke 
(MACE) and death alone. Testosterone supplementa-
tion in men with low testosterone levels was associated 
with a reduced incidence of MACE and death over 3 
years compared with no or ineffective supplementation. 
The results suggest that the positive impact of testos-
terone therapy was mainly on mortality as opposed to 
the number of events, and the benefits were associated 
with the achievement of therapeutic levels of testos-
terone. There was no suggestion of increased risk with 
sustained higher serum levels. 
Sharma et al [82] retrospectively evaluated 83,010 
male veterans with documented low TT levels. The 
subjects were categorised into three groups: testoster-
one therapy with resulting normalisation of TT levels 
(group 1); testosterone therapy without normalisation 
of TT levels (group 2); and did not receive testosterone 
therapy (group 3). The all-cause mortality (hazard ratio 
[HR], 0.53; 95% CI, 0.50–0.55), risk of MI (HR, 0.82; 95% 
CI, 0.71–0.95), and stroke (HR, 0.70; 95% CI, 0.51–0.96) 
were significantly lower in group 1 vs. group 2 (n=25,701; 
median age, 66 years; mean follow-up, 4.6 years).
Wallis et al [83] reported a 5-year follow-up of 10,311 
men on long term testosterone replacement compared 
with a 28,029-control group and found a decreased risk 
in all-cause mortality (HR, 0.67; 95% CI, 0.62–0,73), CV 
events (HR, 0.84; 95% CI, 0.72–0.98) and new cases of 
prostate cancer (HR, 0.60; 95% CI, 0.45–0.80). There 
appeared to be slight increased risk of CV events in 
the first 6 months that could have been related to in-
creased risk caused by low testosterone before patients 
reached therapeutic targets.
CONCLUSIONS
The low levels of testosterone frequently seen in men 
with T2DM are associated with increased comorbidity 
and mortality. Studies with testosterone therapy sug-
gest significant benefits in sexual function, quality of 
life, glycaemic control, anaemia, bone density, fat, and 
lean muscle mass. Longitudinal studies on CV and all-
cause mortality have several logistic problems, related 
to potential increased mortality associated with inade-
quately treated patients and possible selection bias. Fu-
ture studies need to address the impact of depression 
and especially PDE5 inhibitor use, due to the growing 
evidence that these drugs impact CV and all-cause 
morbidity and mortality. Men with T2DM usually re-
quire PDE5 inhibitors as well as testosterone therapy 
to improve sexual function by addressing the multiple 
comorbidities. Restricting therapy to men with classical 
HG is not supported by evidence. The results of life-
style intervention as sole therapy for HG in T2DM are 
disappointing. The balance of evidence suggests that 
men with T2DM, metabolic syndrome and HG are like-
ly to benefit from testosterone therapy combined with 
lifestyle intervention. Meta-analyses of RCTs, rather 
than providing clarification, have further confused the 
issue by including under-powered studies of inadequate 
duration, non-homogenous cohorts, multiple regimes, 
discontinued medication, and inbuilt bias in terms of 
studies included or excluded from analysis.
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